NDA 9452, held by Bluline. Piperazine Citrate.
As of Nov 13, 2026, NDA 9452 (Multifuge), held by Bluline, was first approved by FDA on Jul 12, 1954, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 12, 1954 | Original applicationNew formulation or manufacturer · Standard review | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| MultifugeEQ 500MG BASE/5ML · syrup;oral | Piperazine Citrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
